GlassScriptPhysician profile
Brooke Allman
NPI 1720735913
$1,797.03
in general payments reported to CMS, 2019-2025
15 companies · $55.63 in 2025
The $55.63 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $646 · 2023: $1,019 · 2024: $76.43 · 2025: $55.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $511.72 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $290.80 | 2022-2023 | |
| Janssen Biotech, INC. | $243.78 | 2022-2023 | Stelara, Simponi, Remicade |
| Regeneron Healthcare Solutions, INC. | $240.70 | 2022-2025 | Dupixent |
| Genzyme Corporation | $114.45 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.38 | 2022-2023 | Xifaxan, Trulance |
| Celgene Corporation | $62.29 | 2022-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $44.51 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $43.02 | 2022-2023 | Dificid |
| Ardelyx, INC. | $35.60 | 2023 | Ibsrela |
| Pfizer INC. | $34.26 | 2023 | |
| Vivus LLC | $19.81 | 2022 | |
| Intercept Pharmaceuticals, INC. | $18.63 | 2023 | Ocaliva |
| Lucid Diagnostics INC. | $18.19 | 2023 | |
| Intra-Sana Laboratories | $16.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Allman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.